Pipeline › amycretin
amycretin
Not FDA-approved, and in phase 2 development, not authorised in the European Union.
amylin/GLP-1 agonist, SC/oral, from Novo Nordisk. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- amylin/GLP-1
- Route
- SC/oral
- Sponsor
- Novo Nordisk
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 0 (0 in phase 3)
- Participants enrolled
- 0
- Trials with a reporting date
- 0
- Approved FDA submissions
- 0